Arbutus Biopharma Corporation
ABUS
$5.17
-$0.01-0.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -303.84% | 791.90% | 70.03% | 60.73% | 112.74% |
| Total Depreciation and Amortization | 0.00% | -96.67% | -96.70% | -96.73% | -96.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,239.53% | -81.03% | -229.34% | -33.22% | -101.97% |
| Change in Net Operating Assets | 87.74% | -3,494.69% | 885.15% | 146.02% | -761.35% |
| Cash from Operations | 61.79% | 39.44% | 54.63% | 71.95% | -8.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -110.65% | -80.62% | -112.71% | 16.41% | 58.72% |
| Cash from Investing | -110.64% | -80.62% | -110.15% | 16.41% | 58.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 594.92% | 317.35% | 15.41% | -52.45% | -98.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 594.92% | 317.35% | 15.41% | -52.45% | -98.14% |
| Foreign Exchange rate Adjustments | -119.05% | -350.00% | 103.03% | -340.00% | 362.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,449.70% | 663.81% | -198.13% | 51.51% | -98.29% |